ReviewPLOS global public health2025
Characterization of environmental and clinical surveillance inputs to support prospective integrated modeling of the polio endgame.
Review in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
National, regional, and global poliovirus surveillance needs continue to expand and evolve. The 1988 global resolution to eradicate polio necessitated the creation and support for a global poliovirus surveillance system able to identify poliovirus transmission anywhere and everywhere. Clinical surveillance of patients that present with acute flaccid paralysis (AFP) became an essential tool, and the need for standardized laboratory methods to detect polioviruses isolated from stool samples of AFP patients led to the development of the Global Poliovirus Laboratory Network (GPLN) in 1990. Relatively recently, the GPLN expanded to include environmental surveillance to obtain additional information about poliovirus transmission in some geographies and to increase confidence about the absence of poliovirus transmission after successful eradication and/or the cessation of use of live-attenuated oral poliovirus vaccines (OPVs). Historical polio eradication strategic plans anticipated that successful global poliovirus eradication would lead to reduced requirements for financial investments for a poliovirus-specific surveillance system, and consequent transition of capacity and resources into integrated national disease surveillance systems. However, given the state of the polio endgame with ongoing transmission in several geographies, current global strategic plans include poliovirus-specific surveillance for the foreseeable future. In addition, the development and expansion of genetic testing technologies create new opportunities for poliovirus surveillance system designs. The expected growth (instead of decline) of poliovirus surveillance needs as of 2024, as well as innovations in laboratory technologies and expansion wastewater sampling, raise questions about the tradeoffs of different options and the future of poliovirus surveillance. This descriptive review of poliovirus surveillance evidence as of late 2024 aims to provide national, regional, and global decision makers with an understanding of prospective tradeoffs and uncertainties and to support prospective assumptions relevant for integrated policy, poliovirus transmission, and economic modeling for 2024-2035.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.